

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee
Summary of Main Points from the Meeting held on the 11th of June 2012

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes were approved and will be circulated.

3. Matters Arising

The committee noted the matters arising from the previous meeting.

4. New Medicines Applications

Additions:

- **Balance Active Rx**

Decision: Approved. **Tariff Included Medicine.**

Balance Active Rx (Lactic Acid and Glycogen gel) should be used when a disruption to the normal flora of the vagina leads to the opportunistic growth of anaerobic bacteria has been identified. Balance Active Rx will be used for treatment of patients with recurrent proven bacterial vaginosis. The cost of Balance Active Rx is £5.25 for a 7day course. It is anticipated that 500patients per annum will use Balance Active Rx, with a predicted cost of £2625.00 per annum. Balance Active Rx is suitable for GP prescribing and is in the NWL Formulary.

- **Palonosetron**

Decision: Approved. **Tariff Included Medicine.**

Restricted prescribing to Consultant initiation and SpR continuation in patients receiving subsequent cycles of highly emetogenic chemotherapy or moderately emetogenic chemotherapy where they have failed first line anti-emetic therapy (have Grade 3 N&V) containing a 5-HT3 antagonist (+/- aprepitant where indicated) after the 1st cycle of chemotherapy. Approved for addition to the formulary restricted to consultant initiation in patients receiving subsequent cycles of highly emetogenic chemotherapy or moderately emetogenic chemotherapy where they have failed first line anti-emetic therapy {i.e. have Grade 3 N&V} containing a 5-HT3 antagonist (+/- aprepitant where indicated) on the first cycle. (tariff included)

Ex-panel additions – Individual Funding Request

- **Infliximab for advanced steroid refractory ulcerative colitis in a child, failing medical therapy and immunosuppressants**
- The committee noted and approved this individual funding request form.

5. Medicines Management / Medicines Policy

- **Section 6 – Controlled Drugs**

The CD list has been updated to include Adderall (amphetamine salts), lisdexamfetamine and levobupivacaine epidurals. This section has been updated with contact details for ordering FP10 (PCD) pads, to state that the CD key is held by the Responsible Pharmacist and to reflect electronic and paper prescribing for outpatients, as paper prescriptions are still in use at CNWL. Additionally, this section is updated to reflect the new legislation for prescribing of Schedule 2 – 5 controlled drugs by non-medical pharmacists and nurse prescribers. Guidance on the disposal of CDs has been updated – for partially used ampoules/vials/syringes, the contents are emptied into the sharps bin and the ampoule/vial/syringe is disposed in the sharps bin. An absorbent pad may be placed in the bottom of new sharp bins for areas that dispose of large quantities of CDs.

- **Medicines Committee Terms of Reference and Membership**

The Medicines Committee Terms of Reference and Membership has been updated to reflect appointment of Michelle Jenkins and Cindy Gilmour, Advanced Nurse Practitioners for GUM as Trust PGDs leads (shared role) and Jo Webster as the INWL representative as per Chris Corfield. Deirdre Linnard to follow up on I&A representative and Mark Bower to follow up on consistency of Medicine representation on the committee.

- **Medicines Management Annual Report 2011-12**

The committee noted the above annual report summarising the activities of committees responsible for management of medicines within the Trust, developments throughout the 2011-12 year and reports on results of external assessments. The committee noted section 4.1: CQUIN – Long term urinary catheters and section 5: Medicines incidents and risk reduction. Karen Robertson has sent comments on the patient survey section. Once updated, the report will be sent to the Quality Committee and a summary circulated to the Assurance Committee.

- **PbR Excluded Drugs Guidance 2012-13**

The committee noted the above guidance which has been updated to reflect the individual funding request approval process for 2012-13. C&W's comments on the individual funding request submission form have been sent, but awaiting response. The PbR excluded drugs for specialist areas will be finalised on 15th June 2012.

- **Midwife Exemptions**

The committee noted 8 midwife exemptions. Catherine Wilkins informed the committee that there is national discussion around Carboprost and whether a midwife exemption should be developed

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

- **NWL Integrated Formulary Audits April and May 2012**

The committee noted the audit results and adherence to the NWL Integrated Formulary. This related CQUIN to ensure 90% of prescriptions that require GP continuation should be on the Formulary should be publicised to clinicians.

- **Audit of the safe and secure handling/storage of medicines in clinical areas at Chelsea and Westminster Hospital Foundation Trust March 2012**

The committee noted the audit summary report, results and recommendations. This audit has been sent to the CQC as requested. A total of 23 clinical areas were assessed as part of the audit. Overall compliance with each standard was determined. Areas for improvements included:

- Documentation for all medication fridges of daily medication fridge temperature checks
- Storing the CD order book in the Treatment room if awaiting collection

All medications should be locked away appropriately

6. NICE Guidance May 2012

- **TA255 – Prostate cancer - Cabazitaxel**

The committee noted the negative NICE guidance for Cabazitaxel.

- **TA256 – Atrial fibrillation (stroke prevention) – Rivaroxaban**

The committee noted the NICE guidance for rivaroxaban as an option for the prevention of stroke and systemic embolism within its licensed indication.

7. IVIG Update May 2012

There were 13 IVIG issues in May 2012, with 3 new requests:

- One was for Kawasaki disease (red indication)
- One was for chronic inflammatory demyelinating polyradiculoneuropathy (red indication)
- One was for paraneoplastic syndrome (grey indication)

Surrey PCT approved funding for use of IVIG for paraneoplastic syndrome secondary to carcinoma of unknown origin (grey indication).

8. Items for Noting

- **HIV Drugs Sub-Committee Minutes March 2012**

The committee noted the above minutes.

- **London Cancer New Drugs Group Prioritisation**

The committee noted the Cancer Drugs Fund 2012-13 arrangements for London.

- **Local Chemotherapy Group Minutes May 2012**

The committee noted the above minutes. The eChemo prescribing system, ARIA10, has gone live and training is in progress.

- **Controlled Drug Report Q4 2011-12, updated Q3 AO Report and Q4 AO Report**

The committee noted the Trust quarterly controlled drug reports. The committee noted the discrepancy of 40mLs of Oxycodone liquid missing from Lord Wigram ward, which remains unresolved, and is likely to have resulted from the cumulative effect of inaccurate measuring over a sustained period of time.

9. Papers to go to the Trust Quality Committee

The following papers should be sent to the Trust Quality Committee

- Medicines Committee May 2012 Summary Notes
- Medicines Management Annual Report 2011-12
- Audit of the safe and secure handling/storage of medicines in clinical areas at Chelsea and Westminster Hospital Foundation Trust March 2012
- Controlled Drug Report Q4 2011-12, updated Q3 AO Report and Q4 AO Report
- Dabigatran and rivaroxaban management at C&W following NICE guidance (from the May meeting)

10. AOB

- **Medicines Committee representation on the NWL Formulary Panel**

Catherine Wilkins informed the committee that a PGD for BCG vaccine is in progress. There is a licensed BCG available.

11. Date of the next meeting

Monday 9th of June 2012 8.00 – 9.00 Board Room, Lower Ground Floor

Closing date for papers: Friday 15th of July 2012